Ligand Pharmaceuticals Incorporated Stock Book Value Per Share
| LGND Stock | USD 108.15 1.26 1.15% |
Ligand Pharmaceuticals Incorporated fundamentals help investors to digest information that contributes to Ligand Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ligand Stock. The fundamental analysis module provides a way to measure Ligand Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ligand Pharmaceuticals stock.
Ligand |
Ligand Pharmaceuticals Incorporated Company Book Value Per Share Analysis
Ligand Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Ligand Pharmaceuticals Book Value Per Share | 43.47 X |
Most of Ligand Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ligand Pharmaceuticals Incorporated is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Ligand Pharmaceuticals Incorporated is about 43.465 times. This is 2656.76% lower than that of the Biotechnology sector and 117.48% lower than that of the Health Care industry. The book value per share for all United States stocks is 97.75% higher than that of the company.
Ligand Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ligand Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ligand Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ligand Pharmaceuticals by comparing valuation metrics of similar companies.Ligand Pharmaceuticals is currently under evaluation in book value per share category among its peers.
Ligand Fundamentals
| Return On Equity | -0.0053 | ||||
| Return On Asset | 0.0166 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 1.84 B | ||||
| Shares Outstanding | 19.26 M | ||||
| Shares Owned By Insiders | 2.06 % | ||||
| Shares Owned By Institutions | 98.50 % | ||||
| Number Of Shares Shorted | 844.95 K | ||||
| Price To Earning | 29.74 X | ||||
| Price To Book | 2.51 X | ||||
| Price To Sales | 12.46 X | ||||
| Revenue | 167.13 M | ||||
| Gross Profit | 134.63 M | ||||
| EBITDA | 40.79 M | ||||
| Net Income | (4.03 M) | ||||
| Cash And Equivalents | 147.94 M | ||||
| Cash Per Share | 8.76 X | ||||
| Total Debt | 7.11 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 1.45 X | ||||
| Book Value Per Share | 43.47 X | ||||
| Cash Flow From Operations | 97.05 M | ||||
| Short Ratio | 8.49 X | ||||
| Earnings Per Share | (0.22) X | ||||
| Price To Earnings To Growth | 1.53 X | ||||
| Target Price | 145.63 | ||||
| Number Of Employees | 68 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 2.08 B | ||||
| Total Asset | 941.77 M | ||||
| Retained Earnings | 498.98 M | ||||
| Working Capital | 294.45 M | ||||
| Current Asset | 214.71 M | ||||
| Current Liabilities | 222.82 M | ||||
| Net Asset | 941.77 M |
About Ligand Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ligand Pharmaceuticals Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ligand Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ligand Pharmaceuticals Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Ligand Pharmaceuticals Piotroski F Score and Ligand Pharmaceuticals Altman Z Score analysis. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.